[Hiring] Director, Medical Affairs @Revolution Medicines

Role Description

Reporting to the Country Manager BeLux, the Director, Medical Affairs, BeLux is the medical leader responsible for defining and executing the local medical strategy RevMed portfolio and launches. This role serves as the medical voice within the BeLux Leadership Team, ensuring scientific excellence, compliant medical engagement, and strong alignment between global strategy and local patient, physician, and healthcare system needs.

• Act as the Medical Affairs lead for BeLux, accountable for local medical strategy, execution, and impact across the oncology portfolio.
• Translate global medical and clinical strategies into locally relevant medical plans aligned with country regulations and clinical practice.
• Build and maintain strong relationships with national and regional key opinion leaders, oncology networks, academic institutions, and scientific societies.
• Lead scientific exchange, advisory boards, investigator and other external meetings, press conferences, and congress engagement at country level.
• Collaborate effectively with Midsized Markets, Regional and Global teams by contributing to overall medical affairs strategy.
• Drive local medical strategy across pre-launch, launch, and post-launch phases.
• Provide local medical expertise on evidence generation activities including local studies, real-world evidence initiatives, and investigator-initiated research (where permitted).
• Ensure effective execution of publication plans and scientific communication activities.
• Lead medical launch readiness for oncology products, including training, scientific materials, and field medical engagement plans.
• Partner with Market Access and Commercial teams to support value communication and reimbursement-related interactions from a medical perspective.
• Support lifecycle management activities including new indications, label updates, and competitive positioning.
• Work closely with Market Access, Commercial, Regulatory, Safety, and Corporate Affairs teams to ensure aligned and compliant execution of country plans.
• Provide medical review and approval of non-promotional materials in accordance with local regulations and company policies.
• Build, lead, and develop the country Medical Affairs team when/if applicable, including Medical advisors and MSLs.
• Establish medical processes, governance, and ways of working as part of the country build-out.
• Foster a culture of scientific rigor, compliance, and collaboration.
• Ensure all medical activities comply with local regulations, national and regional codes, and internal company policies.
• Represent Medical Affairs in country governance and risk management forums.

Qualifications

• Advanced degree required (MD, PhD, or PharmD).
• Strong background and experience in oncology required.
• 10+ years’ experience in Medical Affairs with a track record of country leadership.
• Proven value and benefit assessment experience, with deep understanding of BeLux payer decision-making.
• Strong stakeholder management and ability to collaborate with internal and external partners.
• Proven experience supporting oncology product launches in BeLux.
• Strong understanding of the local healthcare system, clinical practice, and regulatory environment.
• Experience in a biotech and/or in a build-out.
• Excellent communication skills, both in person and virtual.
• Proven leadership and people management capabilities; demonstrated success in small but fast growing, entrepreneurial environment.
• Scientific and solution-oriented mindset and capability to move and execute in a rapidly changing, ambiguous environment.
• Strong understanding of local healthcare systems, customer dynamics, and reimbursement environments.
• Willingness to travel nationally and internationally.

Company Description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.

• Current RAS(ON) inhibitors in clinical development include:
• daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor;
• elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor;
• zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor;
• RMC-5127, a RAS(ON) G12V-selective inhibitor.

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.